Cargando…
Impact of active surveillance for prostate cancer on the risk of depression and anxiety
Active surveillance (AS) is a standard treatment option for low risk localized prostate cancer. However, the risk of anxiety and depression compared to other curative strategies, namely radical prostatectomy (RP) and radiotherapy (RT), is controversial. This study consisted in a French representativ...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334351/ https://www.ncbi.nlm.nih.gov/pubmed/35902716 http://dx.doi.org/10.1038/s41598-022-17224-w |
_version_ | 1784759085768376320 |
---|---|
author | Sypre, Davidson Pignot, Géraldine Touzani, Rajae Marino, Patricia Walz, Jochen Rybikowski, Stanislas Maubon, Thomas Branger, Nicolas Salem, Naji Mancini, Julien Gravis, Gwenaelle Bendiane, Marc-Karim Bouhnik, Anne-Deborah |
author_facet | Sypre, Davidson Pignot, Géraldine Touzani, Rajae Marino, Patricia Walz, Jochen Rybikowski, Stanislas Maubon, Thomas Branger, Nicolas Salem, Naji Mancini, Julien Gravis, Gwenaelle Bendiane, Marc-Karim Bouhnik, Anne-Deborah |
author_sort | Sypre, Davidson |
collection | PubMed |
description | Active surveillance (AS) is a standard treatment option for low risk localized prostate cancer. However, the risk of anxiety and depression compared to other curative strategies, namely radical prostatectomy (RP) and radiotherapy (RT), is controversial. This study consisted in a French representative sample of 4174 5-years cancer survivors. Self-reported data, including quality-of-life assessment, were prospectively collected through telephone interviews. Among the 447 survivors with PC, we selected 292 patients with localized prostate cancer, T1–T2 stage, Gleason score ≤ 7 and we compared anxiety and depressive symptoms according to treatment strategy. Among patients on AS, 14.9% received curative treatment during the 5 years of follow-up. Anxiety was reported in 34.3% of cases in the AS group versus 28.6% in the RP group and 31.6% in the RT group (p = 0.400), while depressive symptoms were reported in 14.9% of cases in the AS group versus 10.7% in the RP group and 22.8% in the RT group (p = 0.770). Consumption of anxiolytics reported did not vary significantly between the 3 groups (p = 0.330). In conclusion, patients managed with AS for localized prostate cancer do not report more anxiety or depressive symptoms than patients managed with curative treatment, encouraging the extended use of active surveillance. |
format | Online Article Text |
id | pubmed-9334351 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-93343512022-07-30 Impact of active surveillance for prostate cancer on the risk of depression and anxiety Sypre, Davidson Pignot, Géraldine Touzani, Rajae Marino, Patricia Walz, Jochen Rybikowski, Stanislas Maubon, Thomas Branger, Nicolas Salem, Naji Mancini, Julien Gravis, Gwenaelle Bendiane, Marc-Karim Bouhnik, Anne-Deborah Sci Rep Article Active surveillance (AS) is a standard treatment option for low risk localized prostate cancer. However, the risk of anxiety and depression compared to other curative strategies, namely radical prostatectomy (RP) and radiotherapy (RT), is controversial. This study consisted in a French representative sample of 4174 5-years cancer survivors. Self-reported data, including quality-of-life assessment, were prospectively collected through telephone interviews. Among the 447 survivors with PC, we selected 292 patients with localized prostate cancer, T1–T2 stage, Gleason score ≤ 7 and we compared anxiety and depressive symptoms according to treatment strategy. Among patients on AS, 14.9% received curative treatment during the 5 years of follow-up. Anxiety was reported in 34.3% of cases in the AS group versus 28.6% in the RP group and 31.6% in the RT group (p = 0.400), while depressive symptoms were reported in 14.9% of cases in the AS group versus 10.7% in the RP group and 22.8% in the RT group (p = 0.770). Consumption of anxiolytics reported did not vary significantly between the 3 groups (p = 0.330). In conclusion, patients managed with AS for localized prostate cancer do not report more anxiety or depressive symptoms than patients managed with curative treatment, encouraging the extended use of active surveillance. Nature Publishing Group UK 2022-07-28 /pmc/articles/PMC9334351/ /pubmed/35902716 http://dx.doi.org/10.1038/s41598-022-17224-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Sypre, Davidson Pignot, Géraldine Touzani, Rajae Marino, Patricia Walz, Jochen Rybikowski, Stanislas Maubon, Thomas Branger, Nicolas Salem, Naji Mancini, Julien Gravis, Gwenaelle Bendiane, Marc-Karim Bouhnik, Anne-Deborah Impact of active surveillance for prostate cancer on the risk of depression and anxiety |
title | Impact of active surveillance for prostate cancer on the risk of depression and anxiety |
title_full | Impact of active surveillance for prostate cancer on the risk of depression and anxiety |
title_fullStr | Impact of active surveillance for prostate cancer on the risk of depression and anxiety |
title_full_unstemmed | Impact of active surveillance for prostate cancer on the risk of depression and anxiety |
title_short | Impact of active surveillance for prostate cancer on the risk of depression and anxiety |
title_sort | impact of active surveillance for prostate cancer on the risk of depression and anxiety |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334351/ https://www.ncbi.nlm.nih.gov/pubmed/35902716 http://dx.doi.org/10.1038/s41598-022-17224-w |
work_keys_str_mv | AT sypredavidson impactofactivesurveillanceforprostatecancerontheriskofdepressionandanxiety AT pignotgeraldine impactofactivesurveillanceforprostatecancerontheriskofdepressionandanxiety AT touzanirajae impactofactivesurveillanceforprostatecancerontheriskofdepressionandanxiety AT marinopatricia impactofactivesurveillanceforprostatecancerontheriskofdepressionandanxiety AT walzjochen impactofactivesurveillanceforprostatecancerontheriskofdepressionandanxiety AT rybikowskistanislas impactofactivesurveillanceforprostatecancerontheriskofdepressionandanxiety AT maubonthomas impactofactivesurveillanceforprostatecancerontheriskofdepressionandanxiety AT brangernicolas impactofactivesurveillanceforprostatecancerontheriskofdepressionandanxiety AT salemnaji impactofactivesurveillanceforprostatecancerontheriskofdepressionandanxiety AT mancinijulien impactofactivesurveillanceforprostatecancerontheriskofdepressionandanxiety AT gravisgwenaelle impactofactivesurveillanceforprostatecancerontheriskofdepressionandanxiety AT bendianemarckarim impactofactivesurveillanceforprostatecancerontheriskofdepressionandanxiety AT bouhnikannedeborah impactofactivesurveillanceforprostatecancerontheriskofdepressionandanxiety |